Home › Funds › BENDER ROBERT & ASSOCIATES › VRTX

BENDER ROBERT & ASSOCIATES position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

BENDER ROBERT & ASSOCIATES reported holding 26,658 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$13.9M, representing 2.66% of its reported portfolio and ranking #12 among its reported holdings. BENDER ROBERT & ASSOCIATES has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)26.66K sh
Reported value held$13.94M
Portfolio Weight2.66%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How BENDER ROBERT & ASSOCIATES's VRTX position evolved

BENDER ROBERT & ASSOCIATES first disclosed a stake in VRTX in Q3 2023 at 28,454 shares (US$9.9M). The position peaked in Q3 2026 at 26,658 shares, worth US$13.9M. Across 13 filings, BENDER ROBERT & ASSOCIATES increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 26,658 shares valued at US$13.9M — an increase of 355 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 28.45K $9.89M New
Q4 2023 28.55K $11.62M Hold
Q1 2024 28.17K $11.78M Reduce
Q2 2024 27.29K $12.79M Reduce
Q3 2024 27.13K $12.62M Reduce
Q4 2024 27.31K $11.00M Add
Q1 2025 27.02K $13.10M Reduce
Q2 2025 26.71K $11.89M Reduce
Q3 2025 26.33K $10.31M Reduce
Q4 2025 26.46K $12.00M Add
Q1 2026 26.17K $11.69M Reduce
Q2 2026 26.30K $13.07M Add
Q3 2026 26.66K $13.94M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has BENDER ROBERT & ASSOCIATES held VRTX?

BENDER ROBERT & ASSOCIATES has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is BENDER ROBERT & ASSOCIATES's current position in VRTX?

As of Q3 2026, BENDER ROBERT & ASSOCIATES holds 26.66K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $13.94M, representing 2.66% of its reported portfolio and ranking #12.

Has BENDER ROBERT & ASSOCIATES been buying or selling VRTX?

In the latest 13F filing (Q3 2026), BENDER ROBERT & ASSOCIATES increased its position in VRTX. The position peaked in Q3 2026 at 26.66K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.